List of Evomela drug patents

Evomela is owned by Acrotech.

Evomela contains Melphalan Hydrochloride.

Evomela has a total of 7 drug patents out of which 0 drug patents have expired.

Evomela was authorised for market use on 10 March, 2016.

Evomela is available in powder;intravenous dosage forms.

Evomela can be used as for high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients with multiple myeloma.

The generics of Evomela are possible to be released after 30 January, 2034.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8410077 ACROTECH Sulfoalkyl ether cyclodextrin compositions
Mar, 2029

(6 years from now)

US9200088 ACROTECH Sulfoalkyl ether cyclodextrin compositions
Mar, 2029

(6 years from now)

US11020363 ACROTECH Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same
May, 2030

(7 years from now)

US10864183 ACROTECH Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same
May, 2030

(7 years from now)

US10940128 ACROTECH Injectable melphalan compositions comprising a cyclodextrin derivative and methods of making and using the same
Jun, 2030

(7 years from now)

US9493582 ACROTECH Alkylated cyclodextrin compositions and processes for preparing and using the same
Feb, 2033

(10 years from now)

US10040872 ACROTECH Alkylated cyclodextrin compositions and processes for preparing and using the same
Jan, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Mar 10, 2023

Drugs and Companies using MELPHALAN HYDROCHLORIDE ingredient

Market Authorisation Date: 10 March, 2016

Treatment: For high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients with multiple myeloma

Dosage: POWDER;INTRAVENOUS

How can I launch a generic of EVOMELA before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic